Grégori Gerebtzoff

Grégori Gerebtzoff

Auto-generated profile, based on publicly available information

Grégori Gerebtzoff

Biomedical Research, Novartis Basel Switzerland

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 July 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
GPGiulia Peteani
Giulia Peteani
MHMinh Tam Davide Huynh
Minh Tam Davide Huynh
GGGrégori Gerebtzoff
Grégori Gerebtzoff
RRRaquel Rodríguez-Pérez
Raquel Rodríguez-Pérez
Machine learning (ML) systems can model quantitative structure-property relationships (QSPR) using existing experimental data and make property predictions for new molecules. With the advent of modalities such as targeted protein degraders (TPD), the applicability of QSPR models is questioned and ML usage in TPD-centric projects remains limited. Herein, ML models are developed and evaluated for TPDs’ property predictions, including passive permeability, metabolic clearance, cytochrome P450 inhibition, plasma protein binding, and lipophilicity. Interestingly, performance on TPDs is comparable to that of other modalities. Predictions for glues and heterobifunctionals often yield lower and higher errors, respectively. For permeability, CYP3A4 inhibition, and human and rat microsomal clearance, misclassification errors into high and low risk categories are lower than 4% for glues and 15% for heterobifunctionals. For all modalities, misclassification errors range from 0.8% to 8.1%. Investigated transfer learning strategies improve predictions for heterobifunctionals. This is the first comprehensive evaluation of ML for the prediction of absorption, distribution, metabolism, and excretion (ADME) and physicochemical properties of TPD molecules, including heterobifunctional and molecular glue sub-modalities. Taken together, our investigations show that ML-based QSPR models are applicable to TPDs and support ML usage for TPDs’ design, to potentially accelerate drug discovery.

29 March 2024 in ChemRxiv
Verified
Preprint
Open access
PDF file
MBMaximilian Beckers
Maximilian Beckers
DYDimitar Yonchev
Dimitar Yonchev
SDSandrine Desrayaud
Sandrine Desrayaud
GGGrégori Gerebtzoff
Grégori Gerebtzoff
RRRaquel Rodríguez-Pérez
Raquel Rodríguez-Pérez
After initial triaging using in vitro absorption, distribution, metabolism, and excretion (ADME) assays, pharmacokinetic (PK) studies are the first application of promising drug candidates in living mammals. Pre-clinical PK studies characterize the evolution of the compound’s concentration over time, typically in rodents’ blood or plasma. From this concentration-time (C-t) profiles, PK parameters such as total exposure or maximum concentration can be subsequently derived. An early estimation of compounds’ PK offers the promise of reducing animal studies and cycle times by selecting and designing molecules with increased chances of success at the PK stage. Even though C-t curves are the major readout from a PK study, most machine learning-based prediction efforts have focused on the derived PK parameters instead of C-t profiles, likely due to the lack of approaches to model the underlying ADME mechanisms. Herein, a novel deep learning approach termed DeepCt is proposed for the prediction of C-t curves from the compound structure. Our methodology is based on the prediction of an underlying mechanistic compartmental PK model, which enables further simulations, and predictions of single- and multiple-dose C-t profiles.

21 February 2026 in CPT: Pharmacometrics & Systems Pharmacology
Verified
Journal Article
Open access
HCHenrik Cordes
Henrik Cordes
PAPieter Annaert
Pieter Annaert
PBPavel Balazki
Pavel Balazki
SBSalih Benamara
Salih Benamara
Rodolfo Hernandes BonanRodolfo Hernandes Bonan
Rodolfo Hernandes Bonan
DTDonato Teutonico
Donato Teutonico
Developed at Bayer Technology Services, PK‐Sim and MoBi transitioned into the Open Systems Pharmacology (OSP) Suite, released as free open‐source software in 2017. An active community with stakeholders from academia, industries, and regulators contributes to the continuous improvement of open‐source model‐informed drug development (MIDD). This perspective summarizes the latest advancements presented at the second OSP Community Conference (OSP‐CC) hosted from 29 to 30th of September 2025 at Sanofi Paris, that gathered over 100 attendees from more than 40 institutions.